AqueaTether® Therapeutics focuses on the discovery and development of novel hybrid drug entities beyond the conventional drug classes by using AqueaTether® (AqT®) conjugation and delivery platform technologies. Conventional drug classes, such as small molecules, are often too hydrophobic and may interact with other off-target proteins, leading to potential toxicity and decreased efficacy. Similarly, biologics, such as proteins and antibodies, typically have poor bioavailability and poor in vivo physical and chemical stability. The AqT technologies can overcome these limitations and potentially transform these molecules into better therapeutics.
In an AqT hybrid drug approach, one or few established proprietary AqT molecules are applied to the NCE or NBE of interest to improve aqueous solubility, in vitro stability, efficacy, and other related drug-delivery characteristics. Utilizing an additive chemistry approach, the AqT platform readily provides for a rational evaluation approach to generate simple analog prototypes in order to optimize drug loading, solubility and solubility of the entity. The broad applicability of the AqT molecules and extensive experience of the AqueaTether Therapeutics team can give the advantages of both an accelerated timeframe and an optimized therapeutic entity for you program.
We are a service-orientated technology company dedicated to helping our partners discover and develop novel conjugate drugs.
Our goals
- To utilize the broad applicability of the AqT™ platform technologies across the life science industry
- To increase the impact of AqT related drugs into the market
- To enable our partners utilizing the AqT platform to both time- and cost-effectively create significant value for their programs
AqueaTether® Therapeutics can help solve the following problems
- Converting hydrophobic drugs to water-soluble drugs
- Optimizing antibody-drug conjugates (ADCs): increasing loading and reducing aggregation of the resulting ADC
- Creating new classes of target-specific drug conjugates
- Transforming failed clinical programs by overcoming bioavailability and potential toxicity issues
- Transforming protein, peptide or antibody drug entities that have physical or chemical stability issues
- Transforming oligos/siRNA/miRNA/genes that have current delivery and stability limitations
Together, we look forward to helping you rapidly advance your drug candidates to market with the AqT® platform.